A descriptive evaluation of eligibility for therapy among veterans with chronic hepatitis C virus infection

被引:82
作者
Muir, AJ
Provenzale, D
机构
[1] Duke Univ, Med Ctr, Div Gastroenterol, Durham, NC 27710 USA
[2] Durham Vet Affairs Med Ctr, Div Gastroenterol, Durham, NC USA
关键词
hepatitis C; interferon alfa; substance-related disorders; veterans;
D O I
10.1097/00004836-200203000-00015
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Goal: To assess the number of chronic hepatitis C patients eligible for therapy. Background: Recent studies have shown improved response rates to treatment of chronic hepatitis C infection. However, treatment With interferon alfa has major side effects, and many patients may not be eligible for therapy. Study: One hundred consecutive patients with positive hepatitis C serologies at the Durham Veterans Affairs Medical Center were evaluated. Medical records Were reviewed, and the patients were interviewed. Patients were considered ineligible for therapy if they had severe mental illness, hazardous alcohol consumption, current drug abuse, decompensated cirrhosis, dementia, terminal illness, diabetic ketoacidosis, and severe cardiac or pulmonary disease or if they were homeless. Results: Of the 100 patients, 92% were male and 51% Were African American. The mean age was 47.3 +/- 5.6 years. Only 32 of the 100 patients were eligible for therapy. Hazardous alcohol consumption was present in 44%. Major depressive symptoms were present in 12%. Conclusions: The minority of chronic hepatitis C patients were eligible for therapy. Significant rates of hazardous alcohol consumption and psychiatric disorders were present. For these patients to complete or become eligible for therapy, a multidisciplinary approach with psychiatric and substance abuse treatment will be necessary.
引用
收藏
页码:268 / 271
页数:4
相关论文
共 27 条
[1]  
Babor TF., 1989, Alcohol Health Res World, V13, P371
[2]  
Cheung RC, 2000, AM J GASTROENTEROL, V95, P740, DOI 10.1111/j.1572-0241.2000.01854.x
[3]  
Clark C, 1999, HEPATOLOGY, V30, p364A
[4]  
Feagan BG, 2000, HEPATOLOGY, V32, p307A
[5]  
Ho SB, 2001, AM J GASTROENTEROL, V96, P157
[6]   Hepatitis c in African Americans: Summary of a workshop [J].
Howell, C ;
Jeffers, L ;
Hoofnagle, JH .
GASTROENTEROLOGY, 2000, 119 (05) :1385-+
[7]  
Hu KQ, 2000, HEPATOLOGY, V32, p280A
[8]  
Johnson ME, 1998, AM J GASTROENTEROL, V93, P785
[9]   Morbidity of chronic hepatitis C as seen in a tertiary care medical center [J].
Lee, DH ;
Jamal, H ;
Regenstein, FG ;
Perrillo, RP .
DIGESTIVE DISEASES AND SCIENCES, 1997, 42 (01) :186-191
[10]   Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial [J].
Manns, MP ;
McHutchison, JG ;
Gordon, SC ;
Rustgi, VK ;
Shiffman, M ;
Reindollar, R ;
Goodman, ZD ;
Koury, K ;
Ling, MH ;
Albrecht, JK .
LANCET, 2001, 358 (9286) :958-965